此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Pharmacokinetics of Engasertib in Participants With and Without Hepatic Impairment

2026年11月9日 更新者:Vaderis Therapeutics AG

A Phase 1, Open-label, Parallel Cohort Study to Compare the Pharmacokinetics of Engasertib in Adult Participants With Mild to Moderate Hepatic Impairment Relative to Participants Without Hepatic Impairment

The main objective of this trial is to compare the pharmacokinetics (PK) of engasertib in plasma following administration of a single oral dose in adult participants with mild to moderate hepatic impairment relative to age- and body weight-matched participants without hepatic impairment.

研究概览

地位

尚未招聘

干预/治疗

研究类型

介入性

注册 (估计的)

18

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Vaderis Therapeutics AG
  • 电话号码:+1 844-823-3747
  • 邮箱:info@vaderis.com

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 70年 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Age of 18 to 70 years (both inclusive), at the time of signing the informed consent.
  • Body weight ≥ 50 kg and a body mass index (BMI) within the range 18 to 35 kg/m^2 (both inclusive) at screening.
  • Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical trials.
  • Non-smoker, former smoker or stable non-smoker for at least 3 months prior to screening. Participants must also have abstained from use of other nicotine containing products for at least 3 months before screening.
  • Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol prior to any clinical trial specific procedure.

Participants without hepatic impairment (Cohort 1) only:

  • Overtly healthy as determined by medical evaluation including medical history, physical examination, vital signs and electrocardiogram (ECG).
  • Clinically acceptable results of clinical chemistry, hematology, coagulation, and urinalysis at screening.
  • No known or suspected hepatic impairment; including at screening, meet all the following criteria, as assessed by central laboratory: a) alanine aminotransferase (ALT) ≤ 1.1 x upper limit of normal (ULN); b) aspartate aminotransferase (AST) ≤ 1.2 x ULN; c) Total serum bilirubin ≤ 1.2 x ULN; d) Serum albumin ≥ lower limit of normal (LLN); e) Prothrombin time ≤ 1.2 x ULN.
  • Participant meets the demographic-matching criteria, including body weight (kg) ± 20 % and age ± 15 years of the average of the pooled hepatic impairment cohorts (Cohorts 2 and 3). Attempts will be made to ensure that the male-to-female distribution in Cohort 1, is comparable (i.e., ± 1) to that in the pooled hepatic impairment cohorts (Cohorts 2 and 3).

Participants with impaired hepatic function (Cohorts 2 and 3 only):

  • Documented diagnosis of hepatic impairment that meets the criteria for Class A or B of the Child-Pugh classification, with no clinically significant change in disease status within the 28 days prior to the screening visit, as documented by the participant's recent medical history (e.g., no worsening clinical signs of hepatic impairment, no worsening of total bilirubin or prothrombin time by more than 50%).
  • Participant is willing and able to abide by the lifestyle guidelines described in the protocol.

Exclusion Criteria:

  • Clinically relevant medical condition or malignancy that may significantly alter the absorption, metabolism or elimination of engasertib, constitute a safety risk, or interfere with interpretation of trial results.
  • History or evidence of malabsorption, or gastrointestinal surgery or disease that may significantly affect the absorption, distribution, metabolism or excretion of engasertib.
  • Known or suspected hypersensitivity to engasertib or any component of its formulation.
  • Clinically significant infection or immunodeficiency, including relevant active viral infection.
  • Use of prohibited concomitant medications or therapies that may interfere with the pharmacokinetics of engasertib within the protocol-defined period before dosing.
  • Use of another investigational drug or participation in another clinical trial within 30 days or 5 half-lives of the prior trial intervention, whichever is longer.
  • Clinically significant abnormalities in vital signs, ECG, or renal function that preclude participation.
  • Positive screening for alcohol or drugs of abuse, except where a positive drug screen in participants with hepatic impairment can be explained by permitted concomitant medication.
  • Positive pregnancy test in a female participant of childbearing potential.
  • For Cohorts 2 and 3: clinically relevant disease other than hepatic impairment and its associated manifestations that may affect safety, PK interpretation, or Child-Pugh assessment.
  • For Cohorts 2 and 3: potentially infectious liver disease, including hepatitis B or C.
  • For Cohorts 2 and 3: hepatic carcinoma, hepatorenal syndrome, predicted life expectancy of less than 1 year, severe portal hypertension, severe ascites requiring frequent paracentesis, severe hepatic encephalopathy, recent gastrointestinal hemorrhage, or previous kidney, liver, or heart transplantation.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:基础科学
  • 分配:非随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Cohort 1: No Hepatic Impairment

Participants without hepatic impairment will take a single oral dose of engasertib 40 mg.

Engasertib will be taken orally as capsules.

其他名称:
  • VAD044
实验性的:Cohort 2: Mild Hepatic Impairment

Participants with mild hepatic impairment will take a single oral dose of engasertib 40 mg.

Engasertib will be taken orally as capsules.

其他名称:
  • VAD044
实验性的:Cohort 3: Moderate Hepatic Impairment

Participants with moderate hepatic impairment will take a single oral dose of engasertib 40 mg.

Engasertib will be taken orally as capsules.

其他名称:
  • VAD044

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Area Under the Concentration-time Curve (AUC) from Zero to the Last Quantifiable Concentration (AUC0-tlast) of Engasertib
大体时间:Up to Day 12
Up to Day 12
AUC from Zero to Infinity (AUC0-inf) of Engasertib
大体时间:Up to Day 12
Up to Day 12
Maximum Plasma Concentration (Cmax) of Engasertib
大体时间:Up to Day 12
Up to Day 12

次要结果测量

结果测量
大体时间
Amount Excreted (Ae) in Urine from Time Zero to 72 h (Ae0-72)of Engasertib
大体时间:Up to Day 4
Up to Day 4
Fraction Excreted (Fe) in Urine from Time Zero to 72 h [Fe (%)] of Engasertib
大体时间:Up to Day 4
Up to Day 4
Renal Clearance (CLr) of Engasertib
大体时间:Up to Day 4
Up to Day 4
Percentage of Participants who Experienced Teatment Emergent Adverse Events (TEAEs) and Serious TEAEs
大体时间:Up to Day 12
Up to Day 12

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Katarzyna Jarus-Dziedzic, MD, PhD、BioResearch Group Sp. z o.o.

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年12月1日

初级完成 (估计的)

2027年4月1日

研究完成 (估计的)

2027年4月1日

研究注册日期

首次提交

2026年11月9日

首先提交符合 QC 标准的

2026年11月9日

首次发布 (实际的)

2026年11月16日

研究记录更新

最后更新发布 (实际的)

2026年11月16日

上次提交的符合 QC 标准的更新

2026年11月9日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • ENG-103
  • 2026-526312-37-00 (克蒂斯)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅